Back to homepage

Tag "immunotherapy"

Immunotherapy in inoperable stage III non-small cell lung cancer: a review

Authors: Natasha A Jain MD, Gregory A Otterson MD

This article summarizes the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III nonsmall cell lung cancer.

More▸

Second-line treatment options in hepatocellular carcinoma

Authors: Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.

More▸

Immunotherapy in non-melanoma skin cancer: updates and new perspectives

Authors: Paolo Antonio Ascierto MD, Dirk Schadendorf MD, PhD

This article provides background on NMSC and describes
the updates and new perspectives that were discussed during
the symposium ‘CSCC It Bridge’ held in Naples, Italy, 28–29
November 2018.

More▸

Agents to treat BRAF-mutant lung cancer

Authors: Jean G Bustamante Alvarez MD, MS, Gregory A Otterson MD

Keywords: dabrafenib, immunotherapy, lung neoplasm, protooncogene protein B-raf, trametinib. Citation: Bustamante Alvarez JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs in Context 2019; 8: 212566. DOI: 10.7573/dic.212566 Contributions: Both authors contributed equally to the preparation of this review.

More▸

Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Authors: Daniel I G Cubero MD, PhD, Beatrice Martinez Zugaib Abdalla MD, Jean Schoueri, Fabio Iazetti Lopes, Karine Corcione Turke, Jose Guzman MD, Auro Del Giglio MD, PhD, Carlos D’Apparecida Santos Machado Filho MD, PhD, Vanessa Salzano MD, Dolores Gonzalez Fabra MD

This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.

More▸